GC
VYNT

Globeflex Capital’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Globeflex Capital’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2
Closed – – 567
2016
Q4 		$0 Hold
2
– – ﹤0.01% 554
2016
Q3 		$1K Hold
2
– – ﹤0.01% 444
2016
Q2 		$1K Buy
+2
New +$703 ﹤0.01% 422

Other funds holding VYNT

PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Fairbanks Capital Management Rancho Santa Fe, California $160M AUM 14.36% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DM
Diker Management New York $112M AUM 59.78% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Globeflex Capital's VYNT Position: Q1 2017 in Review

Globeflex Capital sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q1 2017, closing a stake of 2 shares.

Globeflex Capital first reported a position in VYNT in Q2 2016 and held it in 3 quarters. The position peaked at $1K in Q3 2016. 32 funds tracked by Wall St. Rank hold VYNT as of Q1 2017.

  • Globeflex Capital reported no remaining Vyant Bio, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
  • Globeflex Capital sold 2 Vyant Bio, Inc. Common Stock shares in Q1 2017.
  • Globeflex Capital first reported a position in Vyant Bio, Inc. Common Stock in Q2 2016 and held it in 3 quarters.
  • Globeflex Capital's Vyant Bio, Inc. Common Stock position peaked at $1K in Q3 2016.
  • 32 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q1 2017.

Based on Globeflex Capital's 13F filing for Q1 2017, filed 12 May 2017.